Drug Trial Radar · NCT04062201
Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care
Last checked: Nov 19, 2026Latest source record: Aug 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
402
Actual
Start
Aug 22, 2019
Primary completion
Apr 15, 2024
Study completion Apr 15, 2024
Sponsor
- Lead sponsor
- Wits Health Consortium (Pty) LtdAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Regents of the University of California; University of Cape Town; Perinatal HIV Research Unit of the University of the Witswatersrand
- First posted
- Aug 20, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
BEAT Tuberculosis is a phase 3, open label, multi-centre, randomized controlled trial. The purpose of this trial is to compare the efficacy and safety of a Study Strategy consisting of 6 months of bedaquiline (BDQ), delamanid (DLM), and linezolid (LNZ), with levofloxacin (LVX) and clofazimine (CFZ) compared to the current South African Standard of Care (Control Strategy) for 9 months for the treatment of rifampicin resistant (RR-TB) Tuberculosis.
Conditions
- Tuberculosis
- Pre-XDR-TB
- Extensively Drug-Resistant Tuberculosis
- Multi Drug Resistant Tuberculosis
- Rifampicin Resistant Tuberculosis
Interventions
Bedaquiline Oral TabletDrug
Weight Group 16 - 29.9kg: 200mg daily for two weeks; followed by 100mg three times weekly for weeks 3 - 24 Weight Group: 30 - \>50kg: 400mg once daily for 14 days followed by 200mg three times weekly for weeks 3 - 24
Linezolid Oral TabletDrug
Weight Group 16 - 23kg: 180 - 210mg (crush 1 tab and mix in 10ml water, administer 3-3.5ml. Discard rest) Weight Group 23.1 - 29.9kg: 300mg daily Weight Group 30 - 33.9kg: 450mg daily Weight Group 34 - \>50kg: 600mg daily
Delamanid in Oral Dosage FormDrug
Weight Group 16 - 23kg: 25mg twice daily for 24 weeks Weight Group 23.1 - 33.9kg: 50mg twice daily for 24 weeks Weight Group 34 - \>50kg: 100mg twice daily for 8 weeks followed by 200 mg daily for 16 weeks
Clofazimine Oral ProductDrug
Weight Group 16 - 23kg: 100mg three times a week or 50mg daily Weight Group 23.1 - \>50kg: 100mg daily
Levofloxacin Oral TabletDrug
Weight Group 16 - 23kg: 375 - 500mg daily Weight Group 23.1 - 33.9kg: 500mg once daily Weight Group 34 - 50kg: 750mg daily Weight Group \>50kg:1000mg daily
Isoniazid Oral ProductDrug
Weight Group 16 - 23kg: 300mg daily Weight Group 23.1 - 50kg: 400mg daily Weight Group \>50kg: 600mg daily
Ethambutol Oral ProductDrug
Weight Group 16 - 23kg: 400mg daily Weight Group 23.1 - 29.9kg: 600mg daily Weight Group 30 - 50kg: 800mg daily Weight Group \>50kg: 1200mg daily
Pyrazinamide Oral ProductDrug
Weight Group 16 - 23kg: 750mg daily Weight Group 23.1 - 29.9kg: 1000mg daily Weight Group 30 - 33.9kg: 1250mg daily Weight Group 34 - 50kg: 1500mg daily Weight Group \>50kg: 2000mg daily
Linezolid Oral TabletDrug
Weight Group 16 - 23kg: 180 - 210mg (crush 1 tab and mix in 10ml water, administer 3-3.5ml. Discard rest) Weight Group 23.1 - 29.9kg: 300mg daily Weight Group 30 - 33.9kg: 450mg daily Weight Group 34 - \>50kg: 600mg daily
Clofazimine Oral ProductDrug
Weight Group 16 - 23kg: 100mg three times a week or 50mg daily Weight Group 23.1 - \>50kg: 100mg daily
Levofloxacin Oral TabletDrug
Weight Group 16 - 23kg: 375 - 500mg daily Weight Group 23.1 - 33.9kg: 500mg once daily Weight Group 34 - 50kg: 750mg daily Weight Group \>50kg:1000mg daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of participants with a successful outcome at the end of treatmentTime frame: From 24 weeks to 76 weeks depending on assigned strategy and type of TB
- The proportion of participants with a successful outcome at the end of follow up at 76 weeks post treatment initiationTime frame: At the end of follow up at 76 weeks post treatment initiation
- The proportion of participants who experience grade 3 or greater adverse events during treatment and up to 30 days following the end of treatmentTime frame: From treatment initiation to 30 days following the end of treatment
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Jose Pearson TB Hospital
Port Elizabeth, Eastern Cape, South Africa
King DinuZulu Hospital Complex
Durban, KwaZulu-Natal, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.